Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment for relapsed/refractory hematologic malignancies; however, data on patient-reported outcomes in CAR-T are limited. We conducted a longitudinal study of adults with hematologic malignancies receiving CAR-T. We assessed qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, P. Connor, Dhawale, Tejaswini, Newcomb, Richard A., Amonoo, Hermioni L., Lavoie, Mitchell W., Vaughn, Dagny, Karpinski, Kyle, El-Jawahri, Areej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Health Services and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368828/
https://www.ncbi.nlm.nih.gov/pubmed/36995091
http://dx.doi.org/10.1182/bloodadvances.2022009117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368828/
https://www.ncbi.nlm.nih.gov/pubmed/36995091
http://dx.doi.org/10.1182/bloodadvances.2022009117

Ejemplares similares